Effect of aflibercept on human corneal endothelial cells in neovascular age-related macular degeneration: A pilot study Neovasküler Tip yaşa Bağlı Makula Dejenerasyonunda Uygulanan İntravitreal Aflibercept Tedavisinin Korneal Endotel Hücreleri Üzerine Etkisi: Pilot Bir Çalışma


DOĞUİZİ S., ŞEKEROĞLU M. A., Inanc M., Yilmazbas P.

Retina-Vitreus, cilt.28, sa.1, ss.13-18, 2020 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 1
  • Basım Tarihi: 2020
  • Dergi Adı: Retina-Vitreus
  • Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.13-18
  • Anahtar Kelimeler: Aflibercept, Age-related macular degeneration, Cornea endothelium, Specular microscopy, Vascular endothelial growth factor
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: We aimed to evaluate in vivo effects of intravitreal aflibercept injection on human corneal endothelial cells in patients with neovascular age-related macular degeneration (AMD). Methods and Materials: Thirty-four eyes of 34 consecutive patients with unilateral neovascular AMD (19 men, 15 women; mean age 66.4±3.4 years) were recruited to the study. All participants received monthly intravitreal aflibercept injections (2.0 mg, 0.05 ml) for three consecutive months and if needed thereafter. The follow-up period was six months. Noncontact specular microscopy was performed on the central cornea of both eyes at baseline and during follow-up, including the central corneal thickness (CCT), the endothelial cell density (ECD), the coefficient of variation of the cell size (CoV), an objective measure of polymegathism, and the percentage of the hexagonal cells (Hex%), an index of pleomorphism. The untreated contralateral eyes served as the control group. Results: The median number of intravitreal injections per patient was 4 (range, 3-6). The median pre-injection CCT, ECD, CoV, and Hex% was 534.0μm, 2266.0 cells/mm2, 34.5 and 46.0%, respectively. No significant difference was detected in these parameters in either treated and untreated eyes during 6 months after intravitreal aflibercept injection. There was also no difference in CCT, ECD, CoV, and Hex% between the treated eyes and contralateral untreated eyes at baseline and during 6-month follow-up. Conclusion: Repeated intravitreal injections of 2.0 mg aflibercept do not cause any harmful effect on the corneal endothelium evaluated b y specular microscopy in patients with neovascular age-related macular degeneration (AMD).